Skip to content
Alzheon | Preserving Future Memories LogoAlzheon | Preserving Future Memories Logo
LinkedIn
Twitter
  • Home
  • People
    • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Contact
  • Patients
    • Expanded Access Policy
  • Pipeline
    • Our Pipeline
    • Valiltramiprosate Phase 3
    • Valiltramiprosate Development
    • Clinical Data
    • Mechanism of Action
    • New Discoveries
    • Publications
  • Careers
  • Media
    • In The News
    • Press Releases
  • Home
  • People
    • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Contact
  • Patients
    • Expanded Access Policy
  • Pipeline
    • Our Pipeline
    • Valiltramiprosate Phase 3
    • Valiltramiprosate Development
    • Clinical Data
    • Mechanism of Action
    • New Discoveries
    • Publications
  • Careers
  • Media
    • In The News
    • Press Releases
New Year Messagealzheon2022-01-18T17:00:07-05:00

Key Alzheon Publications

    • Click to download Summary of Peer Reviewed Scientific Publications

  2. Abushakra S, et al: APOLLOE4 Phase 3 Study of Oral ALZ-801/Valiltramiprosate in APOE ε4/ε4 Homozygotes with Early Alzheimer’s Disease: Trial Design and Baseline Characteristics, Alzheimer’s & Dementia 2024; 10: e12498.

  3. Tolar M, et al: The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention, International Journal of Molecular Sciences, Special Issue Dementia: From Molecular Pathophysiology to Novel Therapeutic Approaches 2024; 25, 2727.

  4. Hey J. et al: Analysis of Cerebrospinal Fluid, Plasma β‑Amyloid Biomarkers, and Cognition from a 2‑Year Phase 2 Trial Evaluating Oral ALZ‑801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model, Drugs 2024.

  5. Hey J. et al: Effects of Oral ALZ‑801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2‑Year Single‑Arm, Open‑Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease, Drugs 2024.

  6. Tolar M, et al: Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression, International Journal of Molecular Sciences, Special Issue Alzheimer’s Disease: Role and Structure of Soluble Oligomers 2021; 22, 6355.

  7. Abushakra S, et al: APOE ε4/ε4 Homozygotes with Early Alzheimer’s Disease Show Accelerated Hippocampal Atrophy and Cortical Thinning that Correlates with Cognitive Decline, Alzheimer’s & Dementia 2020; 6: e12117.

  8. Tolar M, et al: Aducanumab, Gantenerumab, BAN2401, and ALZ-801—the First Wave of Amyloid-Targeting Drugs for Alzheimer’s Disease with Potential for Near Term Approval, Alzheimer’s Research & Therapy, 2020; 12: 95.

  9. Tolar M, et al: The Path Forward in Alzheimer’s Disease Therapeutics: Reevaluating the Amyloid Cascade Hypothesis, Alzheimer’s & Dementia, 2019; 1-8.

  10. Hey JA, et al: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain, CNS Drugs, 2018; 32(9): 849-861.

  11. Hey JA, et al: Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease, Clinical Pharmacokinetics, 2018; 57(3): 315–333.

  12. Abushakra S, et al: Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential, The Journal of Prevention of Alzheimer’s Disease, 2017; 4(3): 149-156.

  13. Kocis P, et al: Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data, CNS Drugs, 2017; 31(6): 495-509.

  14. Abushakra S, et al: Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect,” The Journal of Prevention of Alzheimer’s Disease, 2016; 3(4): 219-228.

Copyright © Alzheon, Inc. All Rights Reserved. | Privacy Policy

LinkedInX
Page load link
This website uses cookies and third-party services. By clicking "ACCEPT", you confirm that you have read and are agreeing to our privacy policy and the use of ALL cookies. ACCEPT
Go to Top